Systemic Lupus Erythematosus CRISPR Knockout Cell Models for Drug Discovery

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease affecting approximately 5 million people worldwide, with a prevalence of 20-150 cases per 100,000 individuals (WHO, 2023). The disease predominantly affects women (9:1 female-to-male ratio) and has a higher incidence in people of African, Hispanic, and Asian descent. SLE is characterized by multi-organ involvement, including skin, joints, kidneys, and the central nervous system. The 10-year survival rate has improved to over 90% due to better management, but morbidity remains high, with lupus nephritis affecting up to 60% of patients and being a leading cause of death (NCI, 2023). Key risk factors include genetic predisposition (e.g., HLA-DR2/DR3, IRF5, STAT4 variants), environmental triggers (UV light, infections), and hormonal factors.

SLE is ideal for mechanistic studies due to its complex polygenic nature and heterogeneous clinical manifestations. The availability of large public datasets, such as the Lupus Family Registry and Repository (LFRR) and the Accelerating Medicines Partnership (AMP) SLE network, provides extensive genomic and transcriptomic data. Key open questions include the role of type I interferon signaling, the contribution of specific autoantibodies (e.g., anti-dsDNA, anti-Smith), and the mechanisms driving tissue damage. Gene-edited cell models allow researchers to dissect the contribution of individual genetic variants in a controlled background, addressing these questions with precision.

The pathogenesis of SLE involves a breakdown of immune tolerance, leading to autoantibody production and immune complex deposition. Key pathways include:

1. Type I Interferon Pathway: Activation of plasmacytoid dendritic cells (pDCs) by nucleic acid-containing immune complexes triggers TLR7/9 signaling, leading to IFN-alpha production. IFN-alpha then promotes B cell differentiation and T cell activation.

2. B Cell Receptor (BCR) Signaling: Enhanced BCR signaling and defective tolerance checkpoints result in the production of autoreactive B cells and autoantibodies.

3. T Cell Dysregulation: Abnormalities in CD4+ T cell subsets (e.g., increased Th17, reduced Treg) and altered cytokine production (e.g., IL-17, IL-21) contribute to B cell help and tissue inflammation.

4. Neutrophil Extracellular Trap (NET) Formation: Dysregulated NETosis releases self-DNA and autoantigens, further stimulating pDCs and B cells.

Data from TCGA (Pan-Cancer Atlas) and COSMIC (v98) for SLE-associated variants, with frequencies from large GWAS meta-analyses (e.g., Bentham et al., 2015, Nat Genet).

Key signaling networks in SLE include:

• • Type I Interferon Pathway: Central to SLE pathogenesis. Key nodes: TLR7, TLR9, MYD88, IRF7, IRF5, IFNAR1, STAT1, STAT2.
• • NF-kB Pathway: Activated by immune complexes and cytokines. Key nodes: TNFAIP3 (A20), IKK complex, RELA, NFKB1.
• • JAK-STAT Pathway: Mediates cytokine signaling (e.g., IL-6, IL-21, IFN-gamma). Key nodes: JAK1, JAK2, TYK2, STAT3, STAT4.
• • B Cell Receptor Signaling: Key nodes: BLK, LYN, SYK, BTK, PLCG2.
• • T Cell Receptor Signaling: Key nodes: PTPN22, LCK, ZAP70, LAT.

Organoids derived from SLE patient kidney biopsies (e.g., glomerular organoids) are emerging as models for lupus nephritis, allowing study of cell-cell interactions in a 3D context.

Common animal models for SLE include:

• • Spontaneous Models: NZB/W F1 mice, MRL/lpr mice (Fas mutation), BXSB mice (Yaa mutation). These develop lupus-like disease with autoantibodies and nephritis.
• • Induced Models: Pristane-induced lupus in BALB/c mice, chronic graft-versus-host disease (cGVHD) models.
• • Gene-Edited Models: TLR7 transgenic mice (overexpression leads to lupus), IFNAR1 knockout mice (resistant to disease), and IRF5 knockout mice (reduced IFN production).
• • PDX Models: Engraftment of human SLE PBMCs into immunodeficient mice (e.g., NSG) to study human immune responses in vivo.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise genetic modifications in SLE-relevant genes. Examples include:

• • TLR7 Knockout: In THP-1 or HEK293T cells, used to study the role of TLR7 in IFN-alpha production.
• • IFNAR1 Knockout: In HEK293T or Jurkat cells, used to block type I IFN signaling.
• • IRF5 Knockout: In THP-1 cells, used to assess the contribution of IRF5 to IFN responses.
• • TNFAIP3 (A20) Knockout: In HEK293T or THP-1 cells, used to study NF-kB activation.
• • PTPN22 R620W Knock-In: In Jurkat cells, used to model the effect of this risk variant on T cell signaling.

Commercially available, sequence-verified gene-edited cell models accelerate research by providing ready-to-use tools for functional validation, drug screening, and biomarker discovery. These models are available from commercial sources and can be customized for specific research needs.

Gene-edited cell lines are essential for validating the functional role of SLE risk variants. For example:

• • IRF5 Knockout: In THP-1 cells, knockout of IRF5 reduces IFN-alpha production after TLR7 stimulation, confirming its role in the type I IFN pathway.
• • TNFAIP3 Knockout: In HEK293T cells, knockout of A20 leads to increased NF-kB activity, demonstrating its role as a negative regulator.
• • PTPN22 R620W Knock-In: In Jurkat cells, the R620W variant enhances T cell receptor signaling, supporting its association with SLE.

Isogenic cell pairs (e.g., wild-type vs. TLR7 knockout) can be used in high-throughput screens to identify compounds that modulate the type I IFN pathway. For example:

• • Screening for inhibitors of TLR7 signaling using a TLR7 knockout THP-1 cell line as a negative control.
• • Modeling resistance to JAK inhibitors (e.g., baricitinib) using IFNAR1 knockout cells to identify alternative signaling pathways.
• • Testing the efficacy of anti-IFN-alpha antibodies (e.g., anifrolumab) in isogenic cell lines with different IFNAR1 genotypes.

CRISPR-based synthetic lethality screens can identify genes that are essential in SLE-relevant cell types. For example:

• • In THP-1 cells, a genome-wide CRISPR screen can identify genes required for TLR7-induced IFN production, revealing new drug targets.
• • In Jurkat cells, a screen for genes that regulate T cell activation can identify biomarkers of disease activity.
• • In Raji cells, a screen for genes that control autoantibody production can identify targets for B cell-directed therapies.